Edition:
United Kingdom

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

38.00USD
13 Dec 2017
Change (% chg)

$0.40 (+1.06%)
Prev Close
$37.60
Open
$37.65
Day's High
$38.30
Day's Low
$37.50
Volume
36,070
Avg. Vol
40,267
52-wk High
$39.70
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA.WAVE LIFE SCIENCES - WVE-3972-01 DEMONSTRATED SUBSTANTIAL REDUCTION IN DISEASE-ASSOCIATED BIOMARKERS & SUPERIOR POTENCY TO STEREORANDOM OLIGONUCLEOTIDES.WAVE LIFE SCIENCES LTD - CO INTENDS TO INITIATE CLINICAL TRIALS OF WVE-3972-01 IN ALS AND FTD IN Q4 2018.  Full Article

Wave Life Sciences Q3 net loss of $26.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Wave Life Sciences Ltd ::Wave Life Sciences reports third quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - ‍ Wave reported a net loss of $26.1 million for Q3 of 2017, as compared to a net loss of $17.5 million for Q3 of 2016​.Wave Life Sciences Ltd - qtrly loss per share $0.94‍​.Wave Life Sciences -‍ expects capital resources available, anticipated milestone payments to be sufficient to fund expenses, capex needs into mid-2019​.  Full Article

Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD).Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​.  Full Article

Wave Life Sciences appoints chief financial officer
Wednesday, 17 Aug 2016 

Wave Life Sciences Ltd : Wave life sciences appoints Keith Regnante as chief financial officer .Says prior to joining wave, Regnate was a vice president of finance at Shire.  Full Article

Wave Life Sciences' drug for treating huntington's disease receives orphan drug designation
Tuesday, 21 Jun 2016 

Wave Life Sciences Ltd : Wave Life Sciences receives orphan drug designation from FDA for its lead candidate designed to treat Huntington's Disease .On track to file investigational new drug (IND) application in late 2016.  Full Article

Wave Life Sciences says cash resources with $40 mln in payments from Pfizer will fund expenses into 2019
Monday, 16 May 2016 

Wave Life Sciences Ltd : On track to file two investigational new drug applications in late 2016 for its 2 lead allele-specific antisense programs . Expects to report data from its Galnac proof of concept, subcutaneously administered, non-human primate studies in second half of 2016 . Expects cash resources with $40 million in payments from Pfizer collaboration, will fund operating expenses, CAPEX requirements into 2019 .Wave life sciences reports first quarter 2016 financial results and provides business update.  Full Article

Pfizer reports 8 pct passive stake in Wave Life Sciences
Thursday, 12 May 2016 

WAVE Life Sciences Ltd :Pfizer Inc Reports 8 Pct Passive Stake In Wave Life Sciences Ltd As Of May 5, 2016 - SEC filing.  Full Article

UPDATE 1-'Ground-breaking' new drug gives hope in Huntington's disease

LONDON, Dec 11 Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.